Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma
- Provide an investigational agent, 506U78, to physicians for the management of
individual patients with relapsed or refractory T-cell acute lymphoblastic
(lymphocytic) leukemia or T-cell lymphoblastic lymphoma who are not candidates for
entry onto ongoing research clinical trials of higher priority.
- Evaluate the toxic effects of 506U78 when administered as a 2 hour IV infusion 3 days a
week every 21 days in these patients.
- Evaluate the antitumor efficacy of this regimen in terms of rate of complete responses
in these patients.
OUTLINE: Patients receive 506U78 over 2 hours on days 1, 3, and 5. Treatment repeats every
21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease
Patients are followed every 3 months for one year and then every 6 months until death.
PROJECTED ACCRUAL: A minimum of 25 patients will be accrued for this study.
Primary Purpose: Treatment
Provide an investigational agent to physicians for patients who are not candidates for entry onto ongoing research clinical trials of higher priority
Anthony J. Murgo, MD
NCI - Investigational Drug Branch
United States: Federal Government
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|
|Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|
|City of Hope Comprehensive Cancer Center||Duarte, California 91010|
|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida||Tampa, Florida 33612|
|NCI - Pharmaceutical Management Branch||Bethesda, Maryland 20892|